Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Our new book is a comprehensive look at a vital part of medicines development and regulatory affairs. Grab your copy today!
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 14 May 2012 | By Ansis Helmanis,
Based on a 7 May agreement between Brazil's National Health Surveillance Agency (ANVISA) and the Ministry of Agriculture, Livestock and Supply (MAPA), companies will be allowed to produce drugs for both veterinary and human use in the same manufacturing facility as long as the active ingredients and excipients have been approved for both human and veterinary use.
Companies wishing to take advantage of this new approach will be required to obtain Certificates of Good Manufacturing Practices (CBPF) based on the new agreement.
Anvisa will amend the text of Resolution RDC n the17/2010, which addresses the minimum requirements to be followed for compliance with Good Manufacturing Practice for Medicinal Products for Human Use.
Read more:
Anvisa - Anvisa advice on veterinary drugs and human medicines
More Breaking News from RegLink
Tags: CBPF, MAPA, Veterinary, pharmaceutical, brazil, cGMP, drug, GMP